25I-NBOH
Sign in to saveAlso known as Cimbi-27
25I-NBOH (NBOH-2C-I, Cimbi-27, 2C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It is a known metabolite of 25I-NBOMe and has also been encountered as a novel designer drug.
~4 min read
Encyclopedic overview
16 sectionsContents
- Use and effects
- Interactions
- Pharmacology
- Pharmacodynamics
- Chemistry
- Analysis
- Analogues
- History
- Society and culture
- Legal status
- Canada
- Sweden
- United Kingdom
- United States
- See also
- References
25I-NBOH (NBOH-2C-I, Cimbi-27, 2C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It is a known metabolite of 25I-NBOMe and has also been encountered as a novel designer drug.
==Use and effects== The dose range of 25I-NBOH is 300 to 1,000μg, with an estimated typical dose of 700μg. The route of administration is sublingual or buccal.
Excerpted from Wikipedia’s “25I-NBOH” article, available under the CC BY-SA 4.0 licence.